Heart-related mortality in men on ADT: a current perspective

A newly published study in BJU International suggests (unsurprisingly) that androgen deprivation therapy (ADT) is associated with an increased risk of death among men with such cardiovascular conditions as congestive heart failure or prior heart attacks. … READ MORE …

Understanding why placebos can have therapeutic benefit

Regular readers will be familiar with the fact that new drugs for prostate cancer are often tested against a “placebo.” They may also have heard the term “the placebo effect,” which generally implies that some interventions with no known (or theoretically possible) therapeutic benefit can be demonstrated to have a very real therapeutic effect. … READ MORE …

FDA updates risks of adverse effects from treatment with finasteride

The U.S. Food & Drug Adminstration (FDA), yesterday, issued a statement about modifications to the labeling (the product prescribing information) for the two branded formulations of finasteride: Propecia® (finasteride 1 mg) and Proscar® (finasteride 5 mg). These modifications to the product labeling may be relevant to some men with or at risk for prostate cancer. … READ MORE …

Sexual orientation and impact of androgen deprivation therapy

An article by a group of Romanian researchers published in October this year may have some controversial implications — so we want to be very clear that we don’t think too much should be read into it unless their data can be replicated by others. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,169 other followers